Literature DB >> 4087170

Analysis of nonlinear tissue distribution of quinidine in rats by physiologically based pharmacokinetics.

H Harashima, Y Sawada, Y Sugiyama, T Iga, M Hanano.   

Abstract

The nonlinear tissue distribution of quinidine in rats was investigated by a physiologically based pharmacokinetic model. Serum protein binding of quinidine showed a nonlinearity over the in vivo plasma concentration range. The blood-to-plasma concentration ratio (Cb/Cp) of quinidine also showed a concentration dependence. The steady-state volume of distribution (Vss) determined over the plasma concentration range from 0.5 to 10 micrograms/ml was 6.0 +/- 0.45 L/kg. The tissue-to-plasma partition coefficient (Kp) of muscle, skin, liver, lung, and gastrointestinal tract (GI) showed a nonlinearity over the in vivo plasma concentration range of quinidine, suggesting saturable tissue binding. The concentration of quinidine in several tissues and plasma was predicted by a physiologically based pharmacokinetic model using in vitro plasma protein binding and the Cb/Cp of quinidine. The tissue binding parameters were estimated from in vivo Kp values. The predicted concentration curves of quinidine in each tissue and in plasma showed good agreement with the observed values.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4087170     DOI: 10.1007/BF01061478

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  35 in total

1.  The distribution of quinidine in human blood.

Authors:  I E Hughes; K F Ilett; L B Jellett
Journal:  Br J Clin Pharmacol       Date:  1975-12       Impact factor: 4.335

Review 2.  Physiologically based pharmacokinetic models for anticancer drugs.

Authors:  H S Chen; J F Gross
Journal:  Cancer Chemother Pharmacol       Date:  1979       Impact factor: 3.333

3.  Animal scale-up.

Authors:  R L Dedrick
Journal:  J Pharmacokinet Biopharm       Date:  1973-10

4.  Methotrexate pharmacokinetics.

Authors:  K B Bischoff; R L Dedrick; D S Zaharko; J A Longstreth
Journal:  J Pharm Sci       Date:  1971-08       Impact factor: 3.534

5.  Comparison between in-vivo and in-vitro tissue-to-plasma unbound concentration ratios (Kp,f) of quinidine in rats.

Authors:  H Harashima; Y Sugiyama; Y Sawada; T Iga; M Hanano
Journal:  J Pharm Pharmacol       Date:  1984-05       Impact factor: 3.765

6.  Prediction of diazepam disposition in the rat and man by a physiologically based pharmacokinetic model.

Authors:  Y Igari; Y Sugiyama; Y Sawada; T Iga; M Hanano
Journal:  J Pharmacokinet Biopharm       Date:  1983-12

7.  Concentration-time effects of quinidine disposition kinetics in rhesus monkeys.

Authors:  C T Ueda; B Ballard; M Rowland
Journal:  J Pharmacol Exp Ther       Date:  1977-03       Impact factor: 4.030

8.  Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model.

Authors:  N Benowitz; F P Forsyth; K L Melmon; M Rowland
Journal:  Clin Pharmacol Ther       Date:  1974-07       Impact factor: 6.875

9.  Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans.

Authors:  H R Ochs; E Grube; D J Greenblatt; E Woo; G Bodem
Journal:  Am Heart J       Date:  1980-04       Impact factor: 4.749

10.  Effect of propranolol on pharmacokinetics and acute electrocardiographic changes following intravenous quinidine in humans.

Authors:  H R Ochs; D J Greenblatt; E Woo; K Franke; T W Smith
Journal:  Pharmacology       Date:  1978       Impact factor: 2.547

View more
  13 in total

1.  Phosphatidylserine as a determinant for the tissue distribution of weakly basic drugs in rats.

Authors:  N Yata; T Toyoda; T Murakami; A Nishiura; Y Higashi
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

Review 2.  Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.

Authors:  Yumi Yamamoto; Meindert Danhof; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2017-03-09       Impact factor: 4.009

3.  Early Treatment with Quinidine in 2 Patients with Epilepsy of Infancy with Migrating Focal Seizures (EIMFS) Due to Gain-of-Function KCNT1 Mutations: Functional Studies, Clinical Responses, and Critical Issues for Personalized Therapy.

Authors:  Robertino Dilena; Jacopo C DiFrancesco; Maria Virginia Soldovieri; Antonella Giacobbe; Paolo Ambrosino; Ilaria Mosca; Maria Albina Galli; Sophie Guez; Monica Fumagalli; Francesco Miceli; Dario Cattaneo; Francesca Darra; Elena Gennaro; Federico Zara; Pasquale Striano; Barbara Castellotti; Cinzia Gellera; Costanza Varesio; Pierangelo Veggiotti; Maurizio Taglialatela
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

4.  Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy.

Authors:  Silpa Nuthalapati; Qingyu Zhou; Ping Guo; Hua Lv; Stephen Cosenza; M V Ramana Reddy; E Premkumar Reddy; James M Gallo
Journal:  Pharm Res       Date:  2012-06-08       Impact factor: 4.200

5.  Enantioselective tissue distribution of the basic drugs disopyramide, flecainide and verapamil in rats: role of plasma protein and tissue phosphatidylserine binding.

Authors:  K Hanada; S Akimoto; K Mitsui; K Mihara; H Ogata
Journal:  Pharm Res       Date:  1998-08       Impact factor: 4.200

6.  Prediction of the disposition of beta-lactam antibiotics in humans from pharmacokinetic parameters in animals.

Authors:  Y Sawada; M Hanano; Y Sugiyama; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1984-06

7.  KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine.

Authors:  Carol J Milligan; Melody Li; Elena V Gazina; Sarah E Heron; Umesh Nair; Chantel Trager; Christopher A Reid; Anu Venkat; Donald P Younkin; Dennis J Dlugos; Slavé Petrovski; David B Goldstein; Leanne M Dibbens; Ingrid E Scheffer; Samuel F Berkovic; Steven Petrou
Journal:  Ann Neurol       Date:  2014-04-14       Impact factor: 10.422

8.  Soft drugs. 19. Pharmacokinetics, metabolism and excretion of a novel soft corticosteroid, loteprednol etabonate, in rats.

Authors:  N Bodor; W M Wu; T Murakami; S Engel
Journal:  Pharm Res       Date:  1995-06       Impact factor: 4.200

Review 9.  Prediction of the disposition of nine weakly acidic and six weakly basic drugs in humans from pharmacokinetic parameters in rats.

Authors:  Y Sawada; M Hanano; Y Sugiyama; T Iga
Journal:  J Pharmacokinet Biopharm       Date:  1985-10

Review 10.  Utility of CSF in translational neuroscience.

Authors:  Elizabeth C M de Lange
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-02-12       Impact factor: 2.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.